Craft

Novartis

Stock Price

CHF95.7

2024-10-29

Market Capitalization

CHF197.4 B

2024-08-26

Revenue

$54.1 B

FY, 2023

Novartis Summary

Company Summary

Overview
Novartis is a company that researches, develops, manufactures, and markets healthcare products. It comprises two operation divisions: Innovative Medicines and Sandoz. The Innovative Medicines division offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz division provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory.
Type
Public
Status
Active
Founded
1996
HQ
Basel, CH | view all locations
Website
https://www.novartis.com
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Vasant Narasimhan

    Vasant Narasimhan, Chief Executive Officer

  • Kees Roks

    Kees Roks, Chief Audit Officer

    • Harry Kirsch

      Harry Kirsch, Chief Financial Officer

    • Klaus Moosmayer

      Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer

    Operating MetricsView all

    Phase III Trials Products (Biosimilars)

    2
    100.0%

    FY, 2021

    Registration Phase Products (Pharmaceuticals)

    2
    60.0%

    FY, 2021

    Phase I/II Trials Products

    100
    6.5%

    FY, 2022

    LocationsView all

    168 locations detected

    • Basel, BS HQ

      Switzerland

      Novartis Forum 1, Fabrikstrasse 6

    • Broomfield, CO

      United States

      2555 W Midway Blvd

    • Cambridge, MA

      United States

      250 Massachusetts Ave

    • Cambridge, MA

      United States

      Five Cambridge Center, Suite 603

    • Carlsbad, CA

      United States

      1890 Rutherford Rd

    • Deerfield, IL

      United States

      2275 Half Day Rd Ste 200

    and 162 others

    Novartis Financials

    Summary Financials

    Revenue (Q3, 2024)
    $13.2B
    Gross profit (Q3, 2024)
    $12.3B
    Net income (Q3, 2024)
    $3.2B
    Cash (Q3, 2024)
    $13.6B
    EBIT (Q3, 2024)
    $3.6B
    Enterprise value
    $215.9B

    Footer menu